Tislelizumab
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $113,998 | 14 | 1 |
| 2018 | $77,252 | 62 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $113,998 | 14 | 59.6% |
| Consulting Fee | $67,195 | 9 | 35.1% |
| Travel and Lodging | $7,984 | 35 | 4.2% |
| Food and Beverage | $2,073 | 18 | 1.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF TISLELIZUMAB (BGB-A317) PLUS CHEMORADIOTHERAPY FOLLOWED BY TISLELIZUMAB MONOTHERAPY IN NEWLY DIAGNOSED, STAGE III SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (BGB-A317-NSCL-001) | Celgene Corporation | $113,998 | 1 |
Top Doctors Receiving Payments for Tislelizumab
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hazard, KY | $112,570 | 13 |
| Everett Vokes | Hematology & Oncology | Burr Ridge, IL | $11,619 | 10 |
| , M.D | Hematology & Oncology | Sacramento, CA | $10,907 | 9 |
| , MD | Internal Medicine | Philadelphia, PA | $10,108 | 9 |
| , MD | Radiation Oncology | Aurora, CO | $8,359 | 6 |
| , MD | Medical Oncology | Saint Louis, MO | $7,929 | 6 |
| , M.D | Medical Oncology | Chicago, IL | $7,851 | 4 |
| , MD PHD | Anatomic Pathology & Clinical Pathology | New Haven, CT | $7,656 | 9 |
| , M.D.,PHD | Plastic Surgery within the Head & Neck | Columbus, OH | $7,591 | 4 |
| , MD | Medical Oncology | Boston, MA | $6,396 | 3 |
| , DR | Medical Oncology | Boston, MA | $109.37 | 1 |
| , M.D | Hematology & Oncology | Durham, NC | $109.37 | 1 |
| , MD | Medical Oncology | Houston, TX | $46.36 | 1 |
Manufacturing Companies
- Celgene Corporation $191,250
Product Information
- Type Drug
- Total Payments $191,250
- Total Doctors 12
- Transactions 76
About Tislelizumab
Tislelizumab is a drug associated with $191,250 in payments to 12 healthcare providers, recorded across 76 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $113,998 was paid across 14 transactions to 1 doctors.
The most common payment nature for Tislelizumab is "Unspecified" ($113,998, 59.6% of total).
Tislelizumab is associated with 1 research study, including "A PHASE 3, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF TISLELIZUMAB (BGB-A317) PLUS CHEMORADIOTHERAPY FOLLOWED BY TISLELIZUMAB MONOTHERAPY IN NEWLY DIAGNOSED, STAGE III SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (BGB-A317-NSCL-001)" ($113,998).